HomeCompareBIOR vs PLD

BIOR vs PLD: Dividend Comparison 2026

BIOR yields 909.09% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOR wins by $8252641.71M in total portfolio value
10 years
BIOR
BIOR
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full BIOR calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — BIOR vs PLD

📍 BIOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIORPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOR + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOR pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOR
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, BIOR beats the other by $5,766,871,535,478.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOR + PLD for your $10,000?

BIOR: 50%PLD: 50%
100% PLD50/50100% BIOR
Portfolio after 10yr
$4126327.36M
Annual income
$3,392,282,630,246.86/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

BIOR
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-109.2
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOR buys
0
PLD buys
0
No recent congressional trades found for BIOR or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIORPLD
Forward yield909.09%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$8252648.21M$6.50M
Annual income after 10y$6,784,560,004,057.53$5,256,436.18
Total dividends collected$8138900.96M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BIOR vs PLD ($10,000, DRIP)

YearBIOR PortfolioBIOR Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$101,609$90,909.09$11,255$555.24+$90.4KBIOR
2$972,011$863,288.79$13,062$1,018.59+$958.9KBIOR
3$8,758,157$7,718,105.75$15,903$1,926.67+$8.74MBIOR
4$74,364,546$64,993,317.91$20,839$3,823.32+$74.34MBIOR
5$595,318,755$515,748,691.06$30,464$8,166.08+$595.29MBIOR
6$4,495,664,203$3,858,673,134.79$52,054$19,457.30+$4495.61MBIOR
7$32,043,550,537$27,233,189,840.42$109,886$54,188.93+$32043.44MBIOR
8$215,696,715,677$181,410,116,602.38$304,030$186,451.18+$215696.41MBIOR
9$1,372,045,052,584$1,141,249,566,809.58$1,166,125$840,813.32+$1372043.89MBIOR
10$8,252,648,210,323$6,784,560,004,057.53$6,504,190$5,256,436.18+$8252641.71MBIOR

BIOR vs PLD: Complete Analysis 2026

BIORStock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Full BIOR Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this BIOR vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOR vs SCHDBIOR vs JEPIBIOR vs OBIOR vs KOBIOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.